BiotechTube

MGV354 ophthalmic suspension + MGV354 placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Hypertension

Conditions

Ocular Hypertension, Open-Angle Glaucoma

Trial Timeline

Mar 2, 2016 → Sep 20, 2016

NCT ID
NCT02743780

About MGV354 ophthalmic suspension + MGV354 placebo

MGV354 ophthalmic suspension + MGV354 placebo is a phase 1/2 stage product being developed by Novartis for Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02743780. Target conditions include Ocular Hypertension, Open-Angle Glaucoma.

What happened to similar drugs?

4 of 20 similar drugs in Ocular Hypertension were approved

Approved (4) Terminated (0) Active (16)
✅dorzolamide hydrochloride (+) timolol maleateMerckApproved
✅Netarsudil ophthalmic solution 0.02% + Artificial tearsNovartisApproved
✅latanoprost 0.005% (Xalatan)PfizerApproved
✅DEXTENZA®Ocular TherapeutixApproved
🔄ISV-303Sun PharmaceuticalPhase 3
🔄ISV-303Sun PharmaceuticalPhase 3
🔄STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02743780Phase 1/2Completed

Competing Products

20 competing products in Ocular Hypertension

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
36
Mirabegron + PlaceboAstellas PharmaPhase 1
29
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
32
ISV-303Sun PharmaceuticalPhase 3
40
ISV-303Sun PharmaceuticalPhase 3
40
ONO-9054 + LatanoprostOno PharmaceuticalPhase 2
35
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
29
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
26
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
40
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
35
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
35
dorzolamide hydrochloride (+) timolol maleateMerckApproved
43
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
29
SAD448NovartisPhase 1
29